Welcome
The Psoriasis Learning Zone also covers epidemiology, underlying pathophysiology and classification of disease severity from mild to severe psoriasis, as measured by BSA, PASI or PGA. The ‘treatment’ section features comprehensive information on the history, efficacy and safety of available psoriasis treatments, as well as up-to-date insights into the novel therapeutics currently in development.
Want to know more about the changing treatment landscape in psoriasis? Take the interactive EACCME accredited CME to find out more on the burden of psoriasis, its common comorbidities and how the addition of novel treatment types is changing the possible outcomes for patients with moderate-to-severe psoriasis.
The Psoriasis Learning Zone was last updated in May 2020 and the Disease Awareness section reviewed for accuracy by Professor Rolland Gyulai, MD, PhD
COVID-19 in context
Despite ongoing research efforts, COVID-19 is not yet fully understood. As such, there is limited information how this disease affects patients with psoriasis. This section examines how dermatologists around the world have adapted to the crisis, with information on current recommendations and the growing use of teledermatology and the psychological impact of COVID-19 on patients with psoriasis.
Treatment
Read about the established topical, systemic and biologic treatments available for psoriasis as well as novel treatments including tumour necrosis factor-α (TNFα) and interleukin (IL) antagonists.
Guidelines for Psoriasis
Read about, and access, the current guidelines for the management of psoriasis developed by the AAD, EADV, the British Association of Dermatologists and more.
of interest
are looking at
saved
next event
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.